This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Free Reports

Pfizer Ponies Up to Develop Long-acting Growth Hormone

Opko gains $295 million up front for global license to develop, market long-acting HGH.

Third Point's Daniel Loeb Tells Amgen it's Time to Break up

Amgen plans to expound on plans for the company at its Oct. 28 investor meeting.

Changing hospital dynamic leads Becton Dickinson to buy CareFusion

Cash, stock $12.2 billion deal would solidify BD position in infection control, respiratory care.

Amag, Perrigo Buy Lumara in Two-Step Deal Valued at $1.1B

Perrigo gains women's health assets, Amag Pharmaceuticals buys Makena line in the transaction.

Auxilium Adopts Poison Pill in Response to $2.2B Endo Bid

The unsolicited bid comes a week after the Pennsylvania target announced a plant to cut 30% of its workforce.

Cognizant Expands Healthcare Information Technology With $2.7B Trizetto Buy

Teaneck, N.J.-based information technology solutions company Cognizant Technology Solutions is adding the operations of TriZetto to create a fully integrated healthcare technology and operations leader.

Roche, InterMune a Strategic Play in Midst of Inversions

As more companies seek tax savings through inversions, strategic reasons still remain for drug company deals.

Pfizer Bolsters Injectables by Buying InnoPharma

Fresh from AstraZeneca plc's rebuff of its $117 billion offer, Pfizer is setting its sights on a much smaller deal in the U.S. by acquiring InnoPharma.

St. Jude Medical Pays $200M for NeuroTherm

Target produces radiofrequency ablation systems, boosting the buyer's pain management business.

Salix to Invert, Merging With Cosmo Pharma

Building on the M&A trend for tax inversion deals, Salix Pharmaceuticals and Italy's Cosmo Pharmaceuticals plan to merge.

Page 1 of 2
< Previous
Top Rated Stocks Top Rated Funds Top Rated ETFs